Zhejiang Wolwo Bio-Pharmaceutical Co Ltd Total Assets
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd total assets. Based on the latest financial reports, Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) holds total assets worth CN¥2.89 Billion CNY (≈ $423.37 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Zhejiang Wolwo Bio-Pharmaceutical Co Ltd stock valuation for the company's overall valuation and market capitalisation.
Total Assets of Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (2009–2024)
Total assets of Zhejiang Wolwo Bio-Pharmaceutical Co Ltd from 2009 to 2024. This chart illustrates how Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. See Zhejiang Wolwo Bio-Pharmaceutical Co Ltd stock quote for real-time trading data and today's change.
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd - Asset Composition Analysis
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd Total Assets Breakdown (December 2024)
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd total assets breakdown as of December 2024. Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's total assets of CN¥2.89 Billion consist of 61.0% current assets and 39.0% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 41.3% |
| Accounts Receivable | CN¥257.87 Million | 9.5% |
| Inventory | CN¥57.73 Million | 2.1% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥181.53 Million | 6.7% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2009–2024)
This chart illustrates how Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Zhejiang Wolwo Bio-Pharmaceutical Co Ltd current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's current assets represent 61.0% of total assets in 2024, a decrease from 62.2% in 2009.
- Cash Position: Cash and equivalents constituted 41.3% of total assets in 2024, up from 35.8% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, a decrease from 10.0% in 2009.
- Asset Diversification: The largest asset category is accounts receivable at 9.5% of total assets.
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Zhejiang Wolwo Bio-Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Merck & Company Inc
NYSE:MRK
|
USA | $129.80 Billion |
|
AstraZeneca PLC
NASDAQ:AZN
|
USA | $114.02 Billion |
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$201.13 Billion |
|
Novartis AG
MX:NVSN
|
Mexico | MX$118.53 Billion |
|
Pfizer Inc
NYSE:PFE
|
USA | $201.13 Billion |
|
Novo Nordisk A/S
CO:NOVO-B
|
Denmark | Dkr542.90 Billion |
|
Zhejiang Int'L Group Co Ltd
SHE:000411
|
China | CN¥17.31 Billion |
|
SANOFI CONS HEALTHC IND L
NSE:SANOFICONR
|
India | Rs5.47 Billion |
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 14.78 | 10.09 | 21.13 |
| Quick Ratio | 14.33 | 9.77 | 20.26 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.65 Billion | CN¥1.49 Billion | CN¥1.12 Billion |
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.43 |
| Latest Market Cap to Assets Ratio | 0.63 |
| Asset Growth Rate (YoY) | 5.7% |
| Total Assets | CN¥2.71 Billion |
| Market Capitalization | $1.71 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's assets below their book value (0.63x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's assets grew by 5.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (2009–2024)
The table below shows the annual total assets of Zhejiang Wolwo Bio-Pharmaceutical Co Ltd from 2009 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.71 Billion ≈ $396.43 Million |
+5.74% |
| 2023-12-31 | CN¥2.56 Billion ≈ $374.93 Million |
+16.57% |
| 2022-12-31 | CN¥2.20 Billion ≈ $321.62 Million |
+13.76% |
| 2021-12-31 | CN¥1.93 Billion ≈ $282.71 Million |
+20.39% |
| 2020-12-31 | CN¥1.60 Billion ≈ $234.83 Million |
+12.36% |
| 2019-12-31 | CN¥1.43 Billion ≈ $208.99 Million |
+35.01% |
| 2018-12-31 | CN¥1.06 Billion ≈ $154.80 Million |
+24.71% |
| 2017-12-31 | CN¥848.31 Million ≈ $124.13 Million |
+21.73% |
| 2016-12-31 | CN¥696.89 Million ≈ $101.98 Million |
+13.97% |
| 2015-12-31 | CN¥611.49 Million ≈ $89.48 Million |
+15.09% |
| 2014-12-31 | CN¥531.31 Million ≈ $77.75 Million |
+101.29% |
| 2013-12-31 | CN¥263.95 Million ≈ $38.62 Million |
+38.11% |
| 2012-12-31 | CN¥191.11 Million ≈ $27.97 Million |
+29.84% |
| 2011-12-31 | CN¥147.19 Million ≈ $21.54 Million |
+33.17% |
| 2010-12-31 | CN¥110.52 Million ≈ $16.17 Million |
-8.95% |
| 2009-12-31 | CN¥121.38 Million ≈ $17.76 Million |
-- |
About Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceutical products for the diagnosis and treatment of allergic diseases in China and internationally. The company offers Changdi, a dust mine drops; Changhao, an artemisia annua pollen allergen sublingual drops; and Changdian, a dust mite skin prick diagnost… Read more